Autonomic imbalance and metabolic syndrome: Unravelling interactions, mechanisms and outcomes

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 47-49

  Grassi, Guido ^a   Seravalle, Gino ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; EDITORIAL; HEART INFARCTION; HUMAN; HYPOTHESIS; METABOLIC SYNDROME X; METABOLISM; NEUROANATOMY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; SYMPATHETIC TONE;

EID: 29144486187     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000198040.47128.4c     Document Type: Editorial

References (26)

1. Kilyn E. Studien ueber das Hypertonie-Hyperglykamie-Hyperurikamie Syndrome. Zentralblatt für Innere Medizin 1923; 44:105-127.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: in press.
3. Liao Y, Known S, Shaughnessy S, Wallace P, Hutto A, Kenkins AJ, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27:978-983.
4. Kahn R, Buse J, Ferrarinnini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetologia 2005; 48:1684-1699.
5. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381.
6. Fliers E, Kreier F, Voshol PJ, Have Kes LM, Saverwein HP, Kalsbeek A, et al. White adipose tissue: getting nervous. J Neuroendocrinol 2003; 15:1005-1010.
7. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17:719-734.
8. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25:560-563.
9. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensive. J Hypertens 2004; 22:2363-2369.
10. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72.
11. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure and why). J Hypertens 2001; 19:523-528.
12. 2 Grassi G. Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension. J Hypertens 2004; 22:1671-1672.
13. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, et al. Adrenocortical, autonomic and inflammatory causes of the metabolic syndrome. Nested case-control study. Circulation 2002; 106:2659-2665.
14. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005; doi:10.1210/jc.2005-0961 [Epub ahead of print].
15. Grassi G, Dell'Oro R, Quarti Trevano F, Scopelliti F, Seravalle G, Paleari F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48:1359-1365.
16. Lindgren K, Hagelin E, Hansen N, Lind L. Baroreceptor sensitivity is impaired in elderly subjects with metabolic syndrome and insulin resistance. J Hypertens 2006; 24:143-150.
17. 7 Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33:351-375.
18. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164:1066-1076.
19. 9 Mancia G, Sega R, Cesana GC, Bombelli M, Corrao G, Polo Friz H. Metabolic syndrome in PAMELA population: prevalence, prognostic value, out-of-office blood pressures and cardiac damage. J Hypertens 2005; 23(Suppl 2):S134.
20. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22:1991-1998.
21. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 9:40-44.
22. Grassi G, Seravalle G, Dell'Oro R, Quarti Trevano F, Facchini A, Scopelliti F, et al. Sympathetic activation and baroreflex dysfunction in the metabolic syndrome. Eur Heart J 2005; 26(Suppl):345.
23. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
24. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24:583-591.
25. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
26. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 2001; 57:833-838.